peptide facts FAQ

Verify peptide purity and sequence first. Request HPLC chromatograms and mass spectrometry confirmation from your supplier. If your supplier can't produce both within 48 hours, assume the peptide is not research-grade. Dose-response curves for elamipretide are steep and narrow; a 10% purity deficit can shift IC50 values enough to produce statistically non-significant results in models where published data predict significance. Our team has traced more than a dozen failed replication attempts back to peptides that were 85–90% pure but sold as '>95% pure'. The 5–10% impurity fraction included D-amino acid substitutions that don't bind cardiolipin.

Provide the Phase 2 and Phase 3 trial summaries from Stealth BioTherapeutics, which reported mild injection-site reactions and rare hypotension at doses above 4 mg/kg/hr. The most significant safety signal is that Phase 3 trials (TAZPOWER for primary mitochondrial myopathy,BESTOWS for Barth syndrome) did not meet primary efficacy endpoints. Elamipretide is not FDA-approved and remains investigational. Use in human subjects outside a registered clinical trial is not legally permissible; use in in vitro or animal models is standard research practice under institutional biosafety protocols.

Don't. Oral elamipretide undergoes extensive first-pass metabolism in the liver, and the tetrapeptide structure is cleaved by peptidases in the GI tract before reaching systemic circulation. Every clinical trial for SS-31 uses IV infusion (0.25–4 mg/kg/hr) or subcutaneous injection. There are zero peer-reviewed studies demonstrating bioavailability via oral administration. If your experimental model requires oral dosing, SS-31 is the wrong peptide for that route; consider mitochondrial-targeted small molecules like MitoQ instead, which have demonstrated oral bioavailability.

This pattern appears in multiple mitochondrial interventions. Initial improvement followed by stasis or regression as feedback loops adjust. If echocardiographic parameters (ejection fraction, diastolic function) improve through week 8 then flatten, consider dose escalation or adjunct therapies targeting complementary pathways (e.g., NAD+ precursors for SIRT1 activation). Plateauing doesn't indicate toxicity. It signals that the system reached a new equilibrium. Whether that equilibrium is beneficial long term depends on biomarkers beyond functional capacity.

Monitor PGC-1α mRNA expression, mitochondrial DNA copy number, and citrate synthase activity monthly. If biogenesis markers drop by more than 20% from baseline, implement a cycled dosing protocol. 8 weeks on, 2 weeks off. To allow homeostatic recovery. Animal data through 16 weeks shows stable mtDNA copy number, but extrapolating to longer timelines requires direct measurement. No published protocol addresses this scenario because no trial has run long enough to encounter it.

Rotate injection sites across abdomen, thighs, and upper arms on a structured schedule to prevent localised tissue scarring. EMBRACE-HCM reported mild erythema in 22% of subjects at 28 days. Extend that to 6 months and cumulative collagen deposition at repeated sites becomes mechanically plausible. Switching to larger-volume, lower-frequency injections (if compound stability permits) reduces puncture events per month. Oral or transdermal formulations would eliminate this risk but aren't currently available for SS-31.

Yes, provided your institution's IACUC has approved the protocol and you're sourcing the peptide from a legitimate research supplier. Animal research does not require FDA approval of the compound itself. It requires institutional oversight of the study design, humane treatment standards, and scientific justification. Purchase SS-31 with a certificate of analysis confirming ≥98% purity.

It would not change the availability of research-grade SS-31, but it could expand access to clinical-grade elamipretide if the new indication achieved approval. FDA approval is indication-specific: even if SS-31 were approved for Barth syndrome, off-label prescribing for primary mitochondrial myopathy would remain at physician discretion. Research-grade suppliers would continue to offer the peptide for laboratory use regardless of clinical approval status.

No. Marketing SS-31 for human consumption outside an FDA-approved clinical trial or approved drug indication violates the Federal Food, Drug, and Cosmetic Act. Supplements must either qualify as dietary ingredients under DSHEA or receive FDA approval as drugs. SS-31 meets neither criterion. Any supplier marketing it for human use is operating illegally. Researchers should only source from suppliers that explicitly restrict sales to qualified institutions for non-clinical research.

Contact the supplier immediately for compound verification and request analytical documentation (HPLC, mass spectrometry). PE-22-28 is not chemically identical to full-length Spadin. The molecular weights differ (approximately 800 Da for PE-22-28 versus 1,800 Da for Spadin), and this difference is detectable via mass spec. If your protocol requires full-length Spadin and you received PE-22-28, the IC50 values in your concentration-response curves will shift rightward by approximately threefold, potentially misrepresenting your compound's activity. Suppliers using 'Spadin analog' as a catch-all term without specifying the structure create this exact problem.

PE-22-28 demonstrates minimal activity at TREK-2 channels compared to full-length Spadin. Selectivity is approximately 15-fold lower for TREK-2. If your research question involves TREK-2 or requires dual TREK-1/TREK-2 blockade, use full-length Spadin or a Spadin analog that retains the flanking residues contributing to TREK-2 binding. Electrophysiology data from CHO cells expressing TREK-2 showed that 10 μM PE-22-28 produced less than 20% current inhibition, while 3 μM Spadin achieved >70% inhibition under identical conditions. The truncation that improves stability sacrifices receptor promiscuity.

The pathway exists but requires a sponsor willing to fund U.S.-based clinical trials and file an NDA. Given Pinealon's synthetic tripeptide structure (Glu-Asp-Arg), it would likely follow the peptide drug approval pathway. Similar to compounds like exenatide or liraglutide, which took 8–12 years from preclinical development to market approval. If a pharmaceutical sponsor initiated Phase I trials in 2026, FDA approval would be unlikely before 2034–2036 at the earliest. Until then, Pinealon's FDA approved status remains unchanged: not approved for clinical use.

Check for cysteine content in the sequence. Full-length Spadin's disulfide bridge is oxidation-sensitive and degrades rapidly at pH >7.5 or in the presence of trace metals. Store lyophilised powder at −20°C with desiccant, and reconstitute in degassed, slightly acidic buffer (pH 6.0–6.5) immediately before use. PE-22-28 avoids this issue entirely by lacking cysteine residues, which is why stability-sensitive studies default to PE-22-28. If you must use full-length Spadin, add 1 mM DTT (dithiothreitol) or TCEP (tris(2-carboxyethyl)phosphine) to maintain the reduced state, though this introduces a reducing agent variable into your system.

Legitimate suppliers will reject the order. Research-grade peptides require institutional affiliation verification, a clear research protocol description, and confirmation that the compound will not be used for human administration outside approved clinical trials. Ordering without this documentation flags the transaction as non-compliant. Researchers working independently or through private labs should not attempt to purchase Pinealon for personal use. Doing so violates the compound's research-only classification and exposes both the buyer and supplier to regulatory scrutiny. The FDA monitors unapproved drug distribution, and compounds marketed for therapeutic use without approval trigger enforcement actions.

Those terms are misleading. 'FDA-registered' refers to the supplier's facility registration. Not the peptide's approval status. All manufacturers and distributors of drugs and biological products must register with the FDA under 21 CFR Part 207, but registration does not imply that the compounds they sell are FDA-approved for therapeutic use. 'FDA-compliant' is similarly vague. It could mean the supplier follows Good Manufacturing Practices, but it does not mean Pinealon itself has FDA approval. Researchers should verify that suppliers explicitly state the peptide is for research use only and provide documentation confirming amino acid sequencing and purity through independent third-party testing.